OncoMatch/Clinical Trials/NCT05534672
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
Is NCT05534672 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for tuberous sclerosis complex.
The purpose of the RaRE-TS study is to determine safety, tolerability and efficacy of rapamycin versus placebo in a drug resistant epilepsy associated with tuberous sclerosis complex (TSC).
Check if I qualifyExtracted eligibility criteria
Demographics
Prior therapy
Cannot have received: mTOR inhibitor
history of treatment with mTOR inhibitor in the three months prior to screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05534672 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mTOR inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 50 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify